Rheumatoid heavy-duty innovative drug Enreshu domestic officially listed!

Guide: The world's first and only approved T-cell selective co-irritant immunomodulator in the field of rheumatoid arthritis.
On August 9, 2020, the successful launch of Enresu® (Abassu Injection), a self-administered innovative drug for the immune system developed by First Voice Pharmaceuticals and Persimmon in Chinese mainland, also marked the official entry of The ongoing ® in the Chinese mainland.
as the world's first and only approved T-cell selective co-stimulation immunomodulator, Enreshu ® in the Chinese mainland of the full listing, will benefit the domestic 6 million and increasing wind-like patients.
the "Transformational Medicine and Innovative Drugs National Key Laboratory Immunization Summit and EnruiShu ® Listing Conference" in the form of live broadcast of the Beijing venue, the country is divided into Shanghai, Jiangsu, Guangdong and other 19 offline sub-venues.
in addition to the domestic rheumatology treatment field of top experts attended, online live coverage of the domestic rheumatism immunologists more than 12,000 people.
rheumatoid arthritis patients have high heterogeneity and large individual differences.
the use of biomarkers to guide disease prediction, diagnosis, treatment and monitoring will contribute to the overall prevention and control of the disease.
especially in the treatment, biomarker-led program decision-making will be conducive to the identification of personalized treatment plan to shorten the pre-standard treatment time, extend the time of disease control, reduce the occurrence of complications, will greatly improve the clinical benefits of patients.
several studies worldwide show that Abasseno has a better rate of treatment response in patients with anti-guathinaprotein antibodies (ACPA)-positive rheumatoid arthritis.
its unique subcutaneous injection pre-injection injection form, easier for patients to use.
, the listing of Enreshu ®, or the "precision of" China's wind-like treatment into a "new era of precision."
rheumatoid arthritis not only causes a decline in patients' physical function, quality of life and social participation, but also brings great financial burden to the patient's family and society.
according to the 2018 Rheumatoid Arthritis Treatment Guidelines issued by the Chinese Medical Association, the proportion of biologics used in existing patients in China is only 8.3%. according to the
2017 EULAR report, about 70 per cent of patients with wind-like treatment in some developed countries, such as Belgium and France, are treated with biologics;
behind the significant numerical differences, there is a huge unmet demand. "The ® Of Erreshu is the second product to be listed in the field of wind-like treatment after Adesin ®, and is also an important development in the field of wind-like treatment," Ren Jinsheng, chairman and CEO of
First Sound Pharmaceuticals, said in a statement at the listing meeting.
the large number of patients in China, the proportion of patients who choose biologics treatment will increase rapidly in the future, there is a huge unmet demand in this treatment field, the first sound pharmaceutical industry will continue to carry out scientific research and exploration and treatment development in the field of autoimmune disease treatment, in order to fulfill the business mission of 'allowing patients to use more effective drugs at an early date'.
" Abassup has accumulated nearly 15 years of clinical experience since it was approved in the United States in 2005, with global sales of nearly $3 billion in 2019.
this Enreshu ® officially commercialized in Chinese mainland, First Sound Pharmaceuticals is responsible for the Chinese mainland of clinical research and commercial promotion, I believe that china's many patients with the wind type, especially ACPA-positive patients, bring new hope.
.